GLG Pharma
Early Stage
Saving lives with next-generation ovarian cancer treatments.
Analytics
Raised: $0
Aggregate Commitments $
Platform
Wefunder
Start Date
05/29/2018
Close Date
02/22/2019
Min. Goal
$250,000
Max. Goal
$1,070,000
Min. Investment
$100
Security Type
SAFE
Funding Type
RegCF
Valuation Cap
$15,000,000
Discount Rate
0%
Rolling Commitments $
Status
Not Funded
Reporting Date
02/10/2019
Days Remaining
Not Funded
% of Min. Goal
0%
% of Max. Goal
0%
Likelihood of Max
Not Funded
Avg. Daily Raise
$0
Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Location
Jupiter, Florida
Industry
Healthcare & Pharmaceuticals
Tech Sector
GLG Pharma is an oncology company-- and they’re ready to improve cancer treatments. The current treatment for ovarian cancer only leads to about a 40% survival rate. However, GLG Pharma believes that by inhibiting STAT3, a mechanism found in over 30 types of cancer, they can help people respond more successfully to treatment by 10-20%. In fact, their goal is that, in the next five years with their research, they think they could raise the survival rate to 60-70%. So far, GLG was selected by the National Cancer Institute’s PREVENT Cancer Preclinical Drug Development Program for breast cancer, and they received a $3.7M grant from an EU supported fund in Poland for Triple Negative Breast Cancer treatment. Plus, the founder has already had nine drugs be approved by the FDA & EMA.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.